The pituitary-specific transcription factor Pit-i is a cell-specific activator of prolactin and growth hormone gene transcription in the anterior pituitary. Pit-i has also been shown to mediate both thyrotropin-releasing hormone (TRH) and cAMP stimulation of the prolactin and thyrotropin 13-subunit (TSH.J) genes. The molecular mechanism by which Pit-i mediates these simulatory effects remains unclear. At least three Pit-i-binding elements within the TSH.3 gene mediate responsiveness to TRH and cAMP. The present studies were designed to test the hypothesis that phosphorylation is an important modulator of Pit-i interaction with the TSHIJ gene.
TSH18 elements bind less well to nonphosphorylated Pit-i than to phosphorylated Pit-i and are weak activators of gene expression, unlike high-affinity Pit-l binding sites in the prolactin and growth hormone genes. Phosphorylation by protein kinase A or C enhances Pit-i binding to TSHIJ elements 3-to 8-fold. Conversely, phosphorylation generally reduces binding of Pit-i to elements within the prolactin and growth hormone genes. A variation within the consensus sequence for Pit-i binding in TSH13 gene elements [A(A/T)(A/T)AATNCAT in the TSH13 gene versus A(A/T)(A/T)TATNCAT in the prolactin and growth hormone genes] could explain these differences. These elements may limit basal activation of the TSH13 gene by binding less well to nonphosphorylated Pit-i while conferring hormonal stimulation through enhanced binding of phosphorylated Pit-i.
The pituitary-specific transcription factor GHF-1/Pit-1 (hereafter referred to as Pit-1) is important for cell-specific expression of the pituitary hormones prolactin (Prl) and growth hormone (GH) (1) (2) (3) (4) . Pit-1 is a member of a group of the homeobox proteins containing both a homeodomain and a POU domain that are important for DNA binding (4) . Despite the early observations that expression of this gene was primarily limited to GH-secreting (somatotrophs) and Prl-secreting (lactotrophs) cells ofthe anterior pituitary (3, 4) , recent data indicate that Pit-1 is also expressed in the majority of thyrotropin (TSH)-secreting cells (thyrotrophs) (5) . Moreover, a central role for Pit-1 in the development of each of these cell types was demonstrated in dwarf mouse strains containing mutations within the Pit-1 gene (6). It is unlikely, however, that Pit-1 subserves the same cell-specific role for TSH secretion in the thyrotroph as it does for GH and Prl secretion in the somatotroph and lactotroph, since TSH expression precedes Pit-1 expression in the anterior pituitary (5). Alternatively, it has been suggested that Pit-1 is necessary for thyroliberin (TRH) (presumably mediated by protein kinase C) and cAMP (mediated by protein kinase A) regulation of the TSH (3-subunit (TSHf3) gene in humans (7, 8) and rats (9) and the Prl gene in humans (10) and rats (11, 12) . The present study was performed to elucidate the molecular mechanism(s) responsible for hormonal regulation by Pit-1.
We provide evidence that both TRH and cAMP stimulation ofTSHf3 gene expression is mediated by phosphorylation and increased binding of Pit-i to the same cis-acting elements.
METHODS
Piasmid Construction and DNA Transfection. Specific ohgonucleotides and the polymerase chain reaction were used according to previously described methods (7) to introduce specific mutations within a DNA fragment consisting of base pairs (bp) -128 to +37 of the human TSHf3 (hTSHfi) gene. These mutant DNA fragments were inserted between the Kpn 1 (5' end) and HindIII (3' end) sites of a chloramphenicol acetyltransferase (CAT) vector (13) . Construction of luciferase (LUC) vectors containing various regions of the hTSH,3 gene have been described (14) . The wild-type and mutant constructs (20 ,ug) were transiently cotransfected along with a human GH expression plasmid (pTKGH, 5 ,ug) into a clonal rat pituitary cell line (GH3) by a calcium phosphate precipitation technique. Sixteen hours after application of the precipitate, the cell cultures were "shocked" for 2 min with 20o (vol/vol) glycerol in 150 mM NaCI/20 mM Hepes, pH 7.5; in some experiments, TRH (10 nM), forskolin (10 ,uM), or both agents were applied to cell cultures. Basal as well as TRH-, forskolin-, or TRH/forskolin-stimulated expression was measured 24 hr after treatment, and CAT activity was corrected for transfection efficiency by measuring secretion of human GH into the culture medium (7, 8) . Since TRH and forskolin induction of the wild-type construct varied somewhat between experiments (TRH, 3-to 5-fold induction; forskolin, 10-to 15-fold induction), induction of the mutant constructs was always expressed relative to the induction observed with the wild-type construct. In some experiments, LUC constructs (20 ,ug), pTKGH (1 pzg), and a cytomegalovirus expression vector (2 ,ug) containing either no insert ("empty vector," pCMV) or a rat Pit-1 cDNA insert (pCMVPit-1) (7) were cotransfected into the Pit-i-deficient embryonal cell line 293 (8) . Cell cultures were harvested after 24 hr and LUC activity was determined and corrected for transfection efficiency as described above.
Avidin (15) with either purified cAMPdependent protein kinase (PKA) or protein kinase C (PKC) (Promega). In general, 30,000-40,000 cpm of Pit-1 (trichloroacetic acid-precipitable counts) from an in vitro transcription-translation reaction and 1 pmol of biotinylated DNA fragment were used in each binding reaction (8) .
RESULTS AND DISCUSSION
Pit-1 Is a Weak Transactivator of the TSHI3 Gene. Previous work (7, 8) (Fig. 1 ). Cotransfection of different amounts of pCMVPit-1 did not result in a higher degree of stimulation (data not shown). These results are in sharp contrast, to the observation that transfection of a Pit-1 expression vector into a Pit-1-deficient cell line increased basal expression from the GH or Prl promoter 100-fold (4).
TRH and Forskolin Induction of the Wild-Type hTSHfi
Gene. We next tested the effect ofTRH (10 nM), forskolin (10 AuM), or both agents on the expression of CAT reporter plasmids containing either the hTSHB promoter (bp -128 to +37) or a viral promoter (pTKCAT and pRSVCAT) in transfected GH3 cells. TRH and forskolin induction of the hTSHB-CAT construct was 3.9-and 12.0-fold, respectively (Fig. 2) . Induction with the combination of agents was similar to forskolin induction alone, suggesting that these agents may act through a shared pathway. On the other hand, TRH and forskolin induction of pTKCAT and pRSVCAT was less than or equal to 1.9-fold. This level of induction was considered nonspecific in GH3 cells.
Mutation of Pit-i-Binding DNA Elements Reduces Basal Expression and TRH and Forskolin Induction. To begin to understand the importance ofeach of these sites for basal and hormonally stimulated expression, we mutated these sites, either individually or collectively, to sites that should not bind Pit-1 (M mutations; Fig. 3A either unchanged or slightly greater with individual site mutations ( Fig. SA; P1 , P2, or P3) and was significantly increased when all three sites were mutated (Fig. SA, P1-3 1.5-to 2.0-fold by phosphorylation. In vitro phosphorylation of transcription-translation reaction mixtures was confirmed by using [_y-32P]ATP. These data correlate with data on function in GH3 cells (Fig. 4B) (Fig. 6) , this result suggests that phosphorylated Pit-1 binds to site 1 at this DNA sequence. On the other hand, mutation P1 resulted in a nearly 10-fold increase in Pit-1 binding to site 1 and a 25-30%o reduction in Pit-1 binding in response to phosphorylation. Inspection of the hTSHP Pit-1 binding sites (Fig. 6) suggests that the deoxyadenosine at position +4 (conserved in all three sites but different from the consensus sequence, arrowhead) may limit binding of nonphosphorylated Pit-1, since the P1 mutation in the ABCD assay displays a 10-fold increased binding to nonphosphorylated Pit-1. The deoxyguanosine at position +1 was also changed to a deoxyadenosine residue in the P1 mutation. This change, however, is unlikely to be the cause of increased Pit-1 binding, since a deoxyadenosine residue is also found at this same position in site 3 (Fig. 6, Wt3) ; and Wt3 also displays low binding to nonphosphorylated Pit-1. Moreover, each site, but especially sites 1 and 3, displays increased binding to phosphorylated Pit-1 and mutations within the core DNA sequence (Mi or P1) abolish this enhanced binding to site 1. In the case of either the Mi or the P1 mutation of site 1, phosphorylation of Pit-1 actually inhibited binding of Pit-1 to these DNA fragments.
From these data we conclude that the stimulatory effect of TRH or forskolin on hTSH8 gene expression is the result of the phosphorylation of the Pit-1 protein and the subsequent increased binding of this modified protein to at least two of the Pit-1 binding sites in the hTSH,3 gene. The Pit-1 binding sites within the hTSH,8 gene appear to interact, since P mutations at all three sites are required to increase basal expression and since M mutations at either site 1 (Mi) or site 3 (M3) reduce TRH and forskolin induction to the same extent as mutations at all three sites. These Pit-1 binding sites: (i) bind nonphosphorylated Pit-1 less well than the previously described cell-specific sites in the rat Prl and GH genes, (ii) display enhanced binding to phosphorylated Pit-1, and (iii) are responsible for hormonal responsiveness to TRH and forskolin in the hTSHB gene. The deoxyadenosine residue at +4 (Fig. 6, arrow) , which is conserved in each of the TSH,8 sites but is different from the core consensus Pit-1 binding site defined in the rat Prl and GH genes, appears to be responsible for at least part ofthe difference between these elements. Thus, the TSHB gene contains a unique subset of Pit-1 DNA-binding sites that appear to mediate, in part, both TRH and cAMP responsiveness in the thyrotroph.
